Geller NL - Search Results

1

After a treatment breakthrough: a comparison of trial and population-based data for advanced testicular cancer.

Feuer EJ, Frey CM, Brawley OW, Nayfield SG, Cunningham JB, Geller NL, Bosl GJ, Kramer BS. Feuer EJ, et al. Among authors: geller nl. J Clin Oncol. 1994 Feb;12(2):368-77. doi: 10.1200/JCO.1994.12.2.368. J Clin Oncol. 1994. PMID: 7509384

2

Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies.

Bajorin D, Katz A, Chan E, Geller N, Vogelzang N, Bosl GJ. Bajorin D, et al. J Clin Oncol. 1988 May;6(5):786-92. doi: 10.1200/JCO.1988.6.5.786. J Clin Oncol. 1988. PMID: 2835441 Clinical Trial.

3

A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors.

Bosl GJ, Geller NL, Bajorin D, Leitner SP, Yagoda A, Golbey RB, Scher H, Vogelzang NJ, Auman J, Carey R, et al. Bosl GJ, et al. Among authors: geller nl. J Clin Oncol. 1988 Aug;6(8):1231-8. doi: 10.1200/JCO.1988.6.8.1231. J Clin Oncol. 1988. PMID: 2457657 Clinical Trial.

4

The effect of a 7-day delay in chemotherapy cycles on complete response and event-free survival in good-risk disseminated germ cell tumor patients.

Motzer RJ, Geller NL, Bosl GJ. Motzer RJ, et al. Among authors: geller nl. Cancer. 1990 Sep 1;66(5):857-61. doi: 10.1002/1097-0142(19900901)66:5<857::aid-cncr2820660508>3.0.co;2-g. Cancer. 1990. PMID: 1696846 Clinical Trial.

5

Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989).

Motzer RJ, Geller NL, Tan CC, Herr H, Morse M, Fair W, Sheinfeld J, Sogani P, Russo P, Bosl GJ. Motzer RJ, et al. Among authors: geller nl. Cancer. 1991 Mar 1;67(5):1305-10. doi: 10.1002/1097-0142(19910301)67:5<1305::aid-cncr2820670506>3.0.co;2-j. Cancer. 1991. PMID: 1703917 Clinical Trial.

6

Two-drug therapy in patients with metastatic germ cell tumors.

Bajorin DF, Geller NL, Weisen SF, Bosl GJ. Bajorin DF, et al. Among authors: geller nl. Cancer. 1991 Jan 1;67(1):28-32. doi: 10.1002/1097-0142(19910101)67:1<28::aid-cncr2820670106>3.0.co;2-3. Cancer. 1991. PMID: 1845937 Clinical Trial.

7

Serum tumor markers and patient allocation to good-risk and poor-risk clinical trials in patients with germ cell tumors.

Bosl GJ, Geller NL, Bajorin D. Bosl GJ, et al. Among authors: geller nl. Cancer. 1991 Mar 1;67(5):1299-304. doi: 10.1002/1097-0142(19910301)67:5<1299::aid-cncr2820670505>3.0.co;2-4. Cancer. 1991. PMID: 1846774 Clinical Trial.

8

Extragonadal and poor risk nonseminomatous germ cell tumors. Survival and prognostic features.

Toner GC, Geller NL, Lin SY, Bosl GJ. Toner GC, et al. Among authors: geller nl. Cancer. 1991 Apr 15;67(8):2049-57. doi: 10.1002/1097-0142(19910415)67:8<2049::aid-cncr2820670807>3.0.co;2-h. Cancer. 1991. PMID: 1848473

9

VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors.

Bosl GJ, Gluckman R, Geller NL, Golbey RB, Whitmore WF Jr, Herr H, Sogani P, Morse M, Martini N, Bains M, et al. Bosl GJ, et al. Among authors: geller nl. J Clin Oncol. 1986 Oct;4(10):1493-9. doi: 10.1200/JCO.1986.4.10.1493. J Clin Oncol. 1986. PMID: 2428948 Clinical Trial.

10

Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors.

Bosl GJ, Geller NL, Vogelzang NJ, Carey R, Auman J, Whitmore WF, Herr H, Morse M, Sogani P, Chan E. Bosl GJ, et al. Among authors: geller nl. J Clin Oncol. 1987 Mar;5(3):436-40. doi: 10.1200/JCO.1987.5.3.436. J Clin Oncol. 1987. PMID: 2434627

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

268 results

Search Page

Filters